NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies
Results Presented at ASH are a Promising Sign as Company Prepares for STRO-001 Phase 1 Trial SOUTH SAN FRANCISCO, December 12, 2017 -- Two studies presented yesterday at the American Society of Hematology’s annual meeting in Atlanta showed frequent expression of CD74,...
American Society of Hematology (ASH) 2017 – Oral Presentation
High Frequency of CD74 Expression in B-cell Non-Hodgkin’s Lymphoma (NHL) and Targeting with STRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent In Vitro Cytotoxicity and In Vivo Anti-Tumor Activity 2017 ASH NHL Oral Presentation_2017 FINAL
Sutro Marks Two Drug Development Milestones
Receives Celgene Payment, Completes Production for Clinical Trials of Internally-Developed ADC SOUTH SAN FRANCISCO, Oct. 11, 2017 -- Sutro Biopharma has received a manufacturing milestone payment from Celgene and has completed production of STRO-001, its first...
Sutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs
Will Rapidly Advance Promising Drug Candidates to the Clinic SOUTH SAN FRANCISCO, Aug. 10, 2017 – Sutro Biopharma today announced it is refocusing its 2014 immuno-oncology collaboration with Celgene on four programs that are advancing through preclinical...
Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors
Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors
New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts
STRO-001 Targets CD74, Eradicates B-Cell Hematologic Malignancy & Prolongs Survival A Powerful Attack on Multiple Myeloma & Lymphoma SOUTH SAN FRANCISCO, July 17, 2017 – STRO-001, Sutro Biopharma’s antibody drug conjugate targeting the CD74 cell surface...
Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize? – InVivo
https://invivo.pharmamedtechbi.com/IV005100/Cancers-NextGen-Smart-Bomb-Who-Will-Be-First-To-Weaponize
Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century
Modern biotechnology is a young industry. But in just a few decades, the entrepreneurs, scientists, researchers and investors working in this field have firmly established themselves at the forefront of medical innovation. Their work is transforming the way we treat –...
Sutro Appoints Lobacki as Director; Leonard, Krishnan & Levy as Advisors
SOUTH SAN FRANCISCO, April 27, 2017 –Sutro Biopharma Inc. is adding an expert in drug commercialization to its board of directors, appointing clinical and scientific advisors and promoting a key executive as it moves closer to clinical development of STRO-001, an...
American Association for Cancer Research (AACR) 2017 – Poster
Characterization and pre-clinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies 2017 combined MM and NHL AACR FINAL